Azenta Inc
Exchange: NASDAQSector: HealthcareIndustry: Medical Instruments & Supplies
Brooks operates two global, market-leading businesses, Life Sciences and Semiconductor Solutions, each with its own distinct area of focus and expertise. The Life Sciences business, to be operated under the new Azenta brand, provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. On September 20, 2021, the Company announced the pending sale to Thomas H. Lee Partners of its Semiconductor Solutions Group business, which provides industry-leading precision vacuum robotics, integrated automation systems and contamination control solutions to the world's leading semiconductor chip makers and equipment manufacturers as well as collaborative robotics and automation capabilities for multi-market applications. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia.
Did you know?
Generated $1.1 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
—
GoodMoat Value
$30.79
Profile
Valuation (TTM)
Market Cap—
P/E—
EV—
P/B—
Shares Out—
P/Sales—
Revenue—
EV/EBITDA—
Azenta Inc (AZTA) Stock Analysis
Market Cap—
Current Price—
P/E Ratio—
Forward P/E—
PEG Ratio—
EPS—
Book Value—
P/B Ratio—
AZTA Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use -8.9% FCF growth (CAGR)
Cash vs Debt
Net Cash: 231M
Revenue
781M
FY19
389M
FY20
514M
FY21
555M
FY22
551M
FY23
573M
FY24
594M
FY25
Net Income
437M
FY19
65M
FY20
111M
FY21
2.1B
FY22
—
FY23
—
FY24
—
FY25
Did you know?
Earnings per share grew at a 50.0% CAGR.
Azenta Inc (AZTA) Financial Summary
Azenta Inc (AZTA) is a Healthcare company in the Medical Instruments & Supplies industry, listed on NASDAQ..
..
AZTA Key Financial Metrics
| Metric | Value |
|---|
AZTA Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $780.85M | $437.42M |
| FY20 | $388.54M | $64.85M |
| FY21 | $513.70M | $110.75M |
| FY22 | $555.50M | $2.13B |
| FY23 | $551.49M | $-14.64M |
| FY24 | $573.45M | $-164.90M |
| FY25 | $593.82M | $-55.76M |
Azenta Inc (AZTA) Valuation
Based on GoodMoat's DCF model, Azenta Inc has a fair value estimate of $30.79.
About Azenta Inc
Brooks operates two global, market-leading businesses, Life Sciences and Semiconductor Solutions, each with its own distinct area of focus and expertise. The Life Sciences business, to be operated under the new Azenta brand, provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. On September 20, 2021, the Company announced the pending sale to Thomas H. Lee Partners of its Semiconductor Solutions Group business, which provides industry-leading precision vacuum robotics, integrated automation systems and contamination control solutions to the world's leading semiconductor chip makers and equipment manufacturers as well as collaborative robotics and automation capabilities for multi-market applications. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia.